What is Mbiomics?
Founded in 2020, Mbiomics operates at the vanguard of the microbiome biotech sector. The company specializes in the discovery and development of therapeutic interventions derived from the human microbiome, aiming to treat diseases that have historically proven resistant to conventional pharmacological approaches. By integrating advanced computational biology with rigorous laboratory experimentation, Mbiomics has established a robust market position as a key player in the European biotech ecosystem. Its focus on precision medicine and the underlying mechanisms of microbial interaction positions the company as a critical innovator in the development of next-generation therapeutics.
How much funding has Mbiomics raised?
Mbiomics has raised a total of $14.1M across 1 funding round:
Series A
$14.1M
Series A (2023): $14.1M with participation from Bayern Kapital, MIG, and High-Tech Gründerfonds
Key Investors in Mbiomics
Bayern Kapital
Bayern Kapital is a leading venture capital investor in Bavaria, focusing on innovative, technology-oriented startups and companies across various sectors including High-Tech, DeepTech, and Life Sciences.
MIG
MIG is an architecture company specializing in design and engineering in the community, bringing a unique perspective to the investment landscape.
High-Tech Gründerfonds
HTGF is a pre-seed and seed investor focusing on high-tech startups, offering a strong network in both industry and academia, as well as deep tech expertise.
What's next for Mbiomics?
With the successful closure of this major enterprise-level funding, Mbiomics is poised to scale its operational capabilities and expand its research infrastructure. The strategic allocation of these funds will likely prioritize the advancement of lead candidates through preclinical and early clinical trials, while simultaneously strengthening the company's intellectual property portfolio. As the firm moves into its next phase of growth, the focus will shift toward establishing strategic partnerships with larger pharmaceutical entities and refining its manufacturing processes to support future clinical requirements. This capital infusion provides the necessary runway to navigate the complex regulatory landscape of the biotech industry while maintaining a competitive edge in the rapidly evolving microbiome market.
See full Mbiomics company page
